Abstract: The invention relates to a connected hatchery (1) comprising a plurality of devices (22, 23, 24, 25, 3, 42, 43, 44, 45, 46, 47, 5, 62, 63, 64) for handling, processing or vaccinating eggs or chicks distributed along a production line, each of the devices being an automated device fitted with a programmable logic controller (231, 431, 451, 641) capable of producing at least one data stream (F23a, F23b, F23c, F23d, F43a, F43b, F43c, F43d, F43e, F43f, F45a, F45b, F45c, F45d, F45e, F64a, F64b, F64c, F64d) relating to the performance or operations of the said automated device, characterized in that it comprises a data centralizing and processing unit (7) arranged to collect the data streams produced by the programmable logic controllers of said automated devices in order to determine at least one performance indicator (I1, I2, I3) of the production line from one or more of said collected data streams and in order to transmit said performance indicator over a telecommunications network to a remote terminal.

Abstract: A method for monitoring a system for transmitting electrical power for a network for transmitting DC electrical power. The method involves determining, along a measurement segment, a profile of a temperature parameter, determining a theoretical leakage current between the grounding connections of the measurement segment, taking into account the temperature parameter profiles and the load current and voltage, measuring the leakage current between the grounding connections of the measurement segment, and generating an alert if there is a difference between the theoretical and measured leakage current.

Abstract: A power control device for use in an AC power grid for regulating an electrical power a load that is supplied by the AC power grid consumes. The power control device has a frequency sensing functional block for detecting a deviation of the grid frequency from a nominal grid frequency and a logic functional block for performing a load adjustment process during which the power the load consumption is reduced. The load adjustment process is based at least in part on the variation of the frequency of the AC power grid. The load adjustment process is design such that for a plurality of power control devices the individual response produce a grid-wide effect that compensates imbalance between power generation and load in fashion that may reduce unwanted distortion in the AC power grid, such as flicker.

Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C. and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Abstract: A power control device for use in an AC power grid for regulating an electrical power a load that is supplied by the AC power grid consumes. The power control device has a frequency sensing functional block for detecting a deviation of the grid frequency from a nominal grid frequency and a logic functional block for performing a load adjustment process during which the power the load consumption is reduced. The load adjustment process is based at least in part on the variation of the frequency of the AC power grid. The load adjustment process is design such that for a plurality of power control devices the individual response produce a grid-wide effect that compensates imbalance between power generation and load in fashion that may reduce unwanted distortion in the AC power grid, such as flicker.

Abstract: The present invention relates to a composition highly enriched in anti-A and/or anti-B polyclonal immunoglobulins, comprising human polyclonal immunoglobulins, characterized in that at least 80% by weight of the human polyclonal immunoglobulins present in the composition are human anti-A and/or anti-B polyclonal immunoglobulins. The invention also relates to a method for preparing such a composition, and to the use of the composition for preparing a positive control that can be used in a method for assaying anti-A and/or anti-B activity of human normal immunoglobulins, and to use of the composition for determining an individual's blood type.

Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not lass than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not lass than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C. and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the invention method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.